

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

J1011 U.S. PTO  
10/040949  
01/07/02

In re Application of:

Havenga et al.

Serial No.: To be assigned

Filed: January 7, 2002

For: INFECTION WITH CHIMAERIC  
ADENOVIRUSES OF CELLS NEGATIVE  
FOR THE ADENOVIRUS SEROTYPE 5  
COXSACKI ADENOVIRUS RECEPTOR  
(CAR)

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2183-5226US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL740516661US

Date of Deposit with USPS: January 7, 2002

Person making Deposit: Orlena Howell

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

DOCUMENTS

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Issue Date</u>	<u>Inventor</u>
5877011	Armentano et al.	03-02-1999

Foreign Patent Documents

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
WO98/22609	Genzyme	05-28-1998
WO98/50053	Genetic Therapy	11-12-1998
WO00/03029	Introgene B.V.	01-20-2000
WO00/52186	Introgene B.V.	09-08-2000


Other Documents

PCT International Search Report, PCT/NL/99/00435, dated January 21, 2000, 3 pages.

Applicants offer to supply any explanation or discussion of the documents that the Examiner feels is necessary or desirable and which is requested.

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. 1.17(p) is required.

Respectfully submitted,

 Res. No. 44,632  
for

Allen C. Turner  
Registration No. 33,041  
Attorney for Applicants  
TRASKBRITT, PC  
P. O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: (801) 532-1922

Date: January 7, 2002

ACT/bv

Enclosures: Form PTO-1449  
Copy of documents cited

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

*(use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

Application Number	To be assigned
Filing Date	January 7, 2002
First Named Inventor	Havenga et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2183-5226US

[illegible][illegible]Date  
Considered

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

